NCT03929107

Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.

Status unknown Phase 2 Last updated 26 April 2019

What this trial tests

Phase 2 trial testing Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells in B Cell Lymphoma in 80 participants. Status unknown.

Timeline

28 March 2019

Primary endpoint
31 January 2022

30 April 2022

Quick facts

Lead sponsor	Wenbin Qian
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	28 March 2019
Primary completion	31 January 2022
Estimated completion	30 April 2022
Sites	1 location across China

Drugs / interventions tested

• Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells — full drug profile →

Conditions studied

• B Cell Lymphoma — all drugs for B Cell Lymphoma →

Sponsor

Wenbin Qian — full company profile →

Who can join

Adults 18 to 75, any sex, with B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It's a single arm, open label prospective study, in which the safety and efficacy of Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T therapy are evaluated in refractory/relapsed B cell lymphoma patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Recent advances in CAR-T cell engineering.
   Huang R, Li X, He Y, Zhu W, et al · · 2020 · cited 274× · PMID 32616000 · DOI 10.1186/s13045-020-00910-5
2. CAR T-Cell Therapy in Hematological Malignancies.
   Haslauer T, Greil R, Zaborsky N, Geisberger R. · · 2021 · cited 115× · PMID 34445701 · DOI 10.3390/ijms22168996
3. Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
   Bell M, Gottschalk S. · · 2021 · cited 108× · PMID 34177932 · DOI 10.3389/fimmu.2021.684642
4. Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development.
   Tang L, Pan S, Wei X, Xu X, et al · · 2023 · cited 100× · PMID 37803832 · DOI 10.1016/j.ymthe.2023.09.021
5. Cell therapies in the clinic.
   Wang LL, Janes ME, Kumbhojkar N, Kapate N, et al · · 2021 · cited 99× · PMID 34027097 · DOI 10.1002/btm2.10214
6. Next generations of CAR-T cells - new therapeutic opportunities in hematology?
   Tomasik J, Jasiński M, Basak GW. · · 2022 · cited 98× · PMID 36389658 · DOI 10.3389/fimmu.2022.1034707
7. Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
   Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, et al · · 2022 · cited 54× · PMID 35634281 · DOI 10.3389/fimmu.2022.795164
8. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.
   Takacs GP, Flores-Toro JA, Harrison JK. · · 2021 · cited 42× · PMID 33316289 · DOI 10.1016/j.pharmthera.2020.107790